Nuo Therapeutics, Inc. (AURX)
OTCMKTS · Delayed Price · Currency is USD
1.500
0.00 (0.00%)
Apr 15, 2026, 4:00 PM EST

Nuo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-2.51-2.32-3.17-3.17-0.09
Depreciation & Amortization
0.160.10.110.07-
Stock-Based Compensation
0.140.060.020.010.01
Provision & Write-off of Bad Debts
0.090.080.16--
Other Operating Activities
0.02-0.10.02-0.15-
Change in Accounts Receivable
-0.4-0.08-0.32-0.09-
Change in Inventory
-0.080.030.01-0.24-
Change in Accounts Payable
0.22-0.04-00.020.01
Change in Unearned Revenue
1.28----
Change in Other Net Operating Assets
0.240.050.01-0.16-0.05
Operating Cash Flow
-0.86-2.23-3.17-3.71-0.12
Capital Expenditures
-0.27-0.15-0.01-0.06-
Investing Cash Flow
-0.27-0.15-0.01-0.06-
Short-Term Debt Issued
0.5----
Total Debt Issued
0.5----
Net Debt Issued (Repaid)
0.5----
Issuance of Common Stock
0.91.7424.461.37
Financing Cash Flow
1.41.7424.461.37
Miscellaneous Cash Flow Adjustments
---0--
Net Cash Flow
0.27-0.64-1.180.691.25
Free Cash Flow
-1.14-2.39-3.18-3.77-0.12
Free Cash Flow Margin
-34.40%-174.82%-521.76%-3355.12%-
Free Cash Flow Per Share
-0.02-0.05-0.07-0.09-0.00
Cash Interest Paid
0000-
Levered Free Cash Flow
-1.11-1.53-1.85-2.74-0.09
Unlevered Free Cash Flow
-1.11-1.53-1.85-2.74-0.09
Change in Working Capital
1.24-0.04-0.3-0.47-0.04
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.